Brokerages expect Novo Nordisk A/S (NYSE:NVO) to announce sales of $5.23 billion for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Novo Nordisk A/S’s earnings, with estimates ranging from $5.21 billion to $5.26 billion. Novo Nordisk A/S posted sales of $4.43 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.1%. The business is expected to announce its next earnings results on Thursday, August 5th.
On average, analysts expect that Novo Nordisk A/S will report full year sales of $21.41 billion for the current fiscal year, with estimates ranging from $21.18 billion to $21.57 billion. For the next year, analysts forecast that the company will report sales of $23.42 billion, with estimates ranging from $22.99 billion to $23.85 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Novo Nordisk A/S.
Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, May 4th. The company reported $5.45 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $4.64. Novo Nordisk A/S had a return on equity of 71.90% and a net margin of 33.77%. The company had revenue of $5.48 billion for the quarter, compared to analyst estimates of $5.02 billion.
Institutional investors and hedge funds have recently modified their holdings of the stock. HighTower Advisors LLC grew its stake in shares of Novo Nordisk A/S by 13.1% in the first quarter. HighTower Advisors LLC now owns 106,051 shares of the company’s stock worth $7,128,000 after purchasing an additional 12,312 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Novo Nordisk A/S by 42.9% in the first quarter. Rockefeller Capital Management L.P. now owns 156,414 shares of the company’s stock worth $10,544,000 after purchasing an additional 46,920 shares in the last quarter. GW&K Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 17.0% in the first quarter. GW&K Investment Management LLC now owns 16,490 shares of the company’s stock worth $1,112,000 after purchasing an additional 2,401 shares in the last quarter. Traynor Capital Management Inc. grew its stake in shares of Novo Nordisk A/S by 3.0% in the first quarter. Traynor Capital Management Inc. now owns 67,822 shares of the company’s stock worth $4,572,000 after purchasing an additional 1,999 shares in the last quarter. Finally, EagleClaw Capital Managment LLC grew its stake in shares of Novo Nordisk A/S by 3.7% in the first quarter. EagleClaw Capital Managment LLC now owns 36,775 shares of the company’s stock worth $2,479,000 after purchasing an additional 1,325 shares in the last quarter. Hedge funds and other institutional investors own 5.56% of the company’s stock.
Shares of NVO traded down $0.60 during trading on Friday, reaching $88.21. The company’s stock had a trading volume of 41,688 shares, compared to its average volume of 697,785. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.59 and a current ratio of 0.85. The company has a market cap of $207.72 billion, a P/E ratio of 30.84, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $63.22 and a twelve month high of $88.94. The business’s fifty day moving average price is $83.08.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.
Further Reading: How Do Mutual Funds Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.